title: A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
abstract: The occurrence of factor VIII (fVIII) inhibitory antibodies is a rare complication of fVIII substitution therapy in mild/moderate hemophilia A patients. fVIII mutations in certain regions such as the C1 domain are, however, more frequently associated with inhibitor, for reasons which remain unclear. To determine whether inhibitors could map to the mutation site, we analyzed at the clonal level the immune response of such a patient with an inhibitor to wild-type but not self-fVIII and an Arg2150His substitution in the C1 domain. Immortalization of the patient B lymphocytes provided a cell line producing an anti-fVIII IgG4kappa antibody, LE2E9, that inhibited fVIII cofactor activity, following type 2 kinetics and prevented fVIII binding to von Willebrand factor. Epitope mapping with recombinant fVIII fragments indicated that LE2E9 recognized the fVIII C1 domain, but not the Arg2150His-substituted C1 domain. Accordingly, LE2E9 did not inhibit Arg2150His fVIII activity. These observations identify C1 as a novel target for fVIII inhibitors and demonstrate that Arg2150His substitution alters a B-cell epitope in the C1 domain, which may contribute to the higher inhibitor incidence in patients carrying such substitution. (Blood. 2000; 95:156-163)
authors.affiliation: Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Jacquemin
authors.forename: A
authors.initials: A
authors.lastname: Benhida
authors.forename: K
authors.initials: K
authors.lastname: Peerlinck
authors.forename: B
authors.initials: B
authors.lastname: Desqueper
authors.forename: L
authors.initials: L
authors.lastname: Vander Elst
authors.forename: R
authors.initials: R
authors.lastname: Lavend'homme
authors.forename: R
authors.initials: R
authors.lastname: d'Oiron
authors.forename: R
authors.initials: R
authors.lastname: Schwaab
authors.forename: M
authors.initials: M
authors.lastname: Bakkus
authors.forename: K
authors.initials: K
authors.lastname: Thielemans
authors.forename: J G
authors.initials: JG
authors.lastname: Gilles
authors.forename: J
authors.initials: J
authors.lastname: Vermylen
authors.forename: J M
authors.initials: JM
authors.lastname: Saint-Remy
mesh_terms: D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001483:Base Sequence; D001665:Binding Sites; D003001:Cloning, Molecular; D017931:DNA Primers; D005169:Factor VIII / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D005803:Genes, Immunoglobulin; D006467:Hemophilia A / Q000097:blood* / Q000235:genetics; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007135:Immunoglobulin Variable Region / Q000235:genetics; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D017931:DNA Primers; D007074:Immunoglobulin G; D007135:Immunoglobulin Variable Region; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D005169:Factor VIII